Spots Global Cancer Trial Database for acute
Every month we try and update this database with for acute cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Crenolanib in Subjects With Relapsed/Refractory AML With FLT3 Activating Mutations | NCT01522469 | Relapsed or Ref... | Crenolanib Besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Therapy-Optimization Trial for the Treatment of Acute Myeloid Leukemias (AML) in Children and Adolescents | NCT00111345 | Myeloid Leukemi... | Anthracyclines liposomal dauno... 2-CDA AI | 1 Day - 18 Years | University Hospital Muenster | |
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00905398 | Precursor B-Cel... Acute Lymphobla... | Nilotinib | 18 Years - 75 Years | Universidade Federal do Rio de Janeiro | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00186875 | Acute Lymphobla... Lymphoma, Lymph... | Etoposide, cyta... methotrexate, t... mitoxantrone, c... L-asparaginase,... chemotherapy, i... Hematopoietic S... Natural Killer ... | - 21 Years | St. Jude Children's Research Hospital | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia | NCT01700413 | Di Novo Acute M... | Idarubicin | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Pediatric Longitudinal Cohort Study of Chronic Pancreatitis | NCT03672422 | Pancreatitis, C... Pancreatitis, A... | Blood sample Patient questio... Saliva sample Urine sample | 0 Years - 17 Years | University of Iowa | |
| Safety and Efficacy of Marqibo in Relapsed Acute Lymphoblastic Leukemia | NCT00495079 | Acute Lymphobla... | Marqibo® (vincr... | 18 Years - | Spectrum Pharmaceuticals, Inc | |
| Erwinase for Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) (IND 104224) | NCT00928200 | Relapsed Acute ... Allergy to PEG ... Allergy to Nati... | Erwinase Vincristine Dexamethasone Doxorubicin Cytarabine Methotrexate Triple Intrathe... Dexrazoxane | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| AEG35156 in Combination With High-dose Cytarabine and Idarubicin in AML Following Failure of a Single Standard Dose Cytarabine Based Frontline Induction Regimen | NCT01018069 | Leukemia | AEG35156 | 18 Years - | Aegera Therapeutics | |
| Trial of CPX-351 in Adult Patients With First Relapse Acute Myeloid Leukemia (AML) | NCT00822094 | Acute Myeloid L... | CPX-351 Intensive Salva... | 18 Years - 65 Years | Jazz Pharmaceuticals | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| A Study Of Panobinostat In Children With Refractory Hematologic Malignancies | NCT01321346 | Lymphoblastic L... Myelogenous Leu... Hodgkin's Disea... Non-Hodgkin's L... | Panobinostat Cytarabine Panobinostat | 8 Years - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | NCT01483690 | Acute Lymphobla... Precursor B-Cel... Precursor T-Cel... | Decitabine Vorinostat Vincristine Dexamethasone Mitoxantrone Pegaspargase Methotrexate | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | NCT00037583 | Acute Myeloid L... | Gemtuzumab Ozog... | 18 Years - 59 Years | Wyeth is now a wholly owned subsidiary of Pfizer | |
| Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia | NCT00905398 | Precursor B-Cel... Acute Lymphobla... | Nilotinib | 18 Years - 75 Years | Universidade Federal do Rio de Janeiro | |
| Efficacy and Toxicity of Increasing Doses of Idarubicin, Cytarabine and G-CSF in Acute Myeloid Leukemia | NCT01700413 | Di Novo Acute M... | Idarubicin | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| Lentivirally Redirected CD123 Autologous T Cells in AML | NCT03766126 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 18 Years - | University of Pennsylvania | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| CD123 Redirected T Cells for AML in Pediatric Subjects | NCT04678336 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 1 Year - 29 Years | University of Pennsylvania | |
| An Observational Post Authorisation Study to Evaluate Safety and Efficacy in Patients Receiving Azacitidine in Daily Clinical Practice in the Netherlands | NCT02891551 | Myelodysplastic... Leukemia, Myelo... Leukemia, Myelo... | 18 Years - | Celgene | ||
| Natural Killer (NK) Cell Transplantation for AML | NCT00187096 | Acute Myeloid L... | Cyclophosphamid... Natural Killer ... CliniMACS Syste... | - 21 Years | St. Jude Children's Research Hospital | |
| A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma | NCT01614197 | Lymphoblastic L... Lymphoblastic L... Peripheral T-ce... | Temsirolimus Etoposide Cyclophosphamid... Methotrexate Hydrocortisone Cytarabine | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Natural Killer (NK) Cell Transplantation for AML | NCT00187096 | Acute Myeloid L... | Cyclophosphamid... Natural Killer ... CliniMACS Syste... | - 21 Years | St. Jude Children's Research Hospital | |
| Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy | NCT04090736 | Leukemia, Myelo... | Pevonedistat Azacitidine | 18 Years - | PETHEMA Foundation | |
| Pediatric Longitudinal Cohort Study of Chronic Pancreatitis | NCT03672422 | Pancreatitis, C... Pancreatitis, A... | Blood sample Patient questio... Saliva sample Urine sample | 0 Years - 17 Years | University of Iowa | |
| Epigenetic Reprogramming in Relapse/Refractory AML | NCT03263936 | Acute Myelogeno... | Decitabine Vorinostat Filgrastim (G-C... Fludarabine Cytarabine | 1 Year - 25 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| CD123 Redirected T Cells for AML in Pediatric Subjects | NCT04678336 | Acute Myeloid L... Acute Myeloid L... Acute Myeloid L... | CART123 cells; ... | 1 Year - 29 Years | University of Pennsylvania | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| Risk Adapted Treatment for Primary Acute Myeloid Leukemia (AML) | NCT01723657 | Leukemia, Myelo... | Ara-C Autologous peri... Allogeneic matc... G-CSF CD34+ selection... Mylotarg purgin... | 18 Years - 70 Years | Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias | |
| A Pilot Study of Decitabine and Vorinostat With Chemotherapy for Relapsed ALL | NCT01483690 | Acute Lymphobla... Precursor B-Cel... Precursor T-Cel... | Decitabine Vorinostat Vincristine Dexamethasone Mitoxantrone Pegaspargase Methotrexate | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia | NCT00186875 | Acute Lymphobla... Lymphoma, Lymph... | Etoposide, cyta... methotrexate, t... mitoxantrone, c... L-asparaginase,... chemotherapy, i... Hematopoietic S... Natural Killer ... | - 21 Years | St. Jude Children's Research Hospital | |
| A Phase II Study of Crenolanib in Relapsed/Refractory Acute Myeloid Leukemia Patients With FLT3 Activating Mutations | NCT01657682 | Acute Myeloid L... | Crenolanib besy... | 18 Years - | Arog Pharmaceuticals, Inc. | |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia | NCT01793025 | Acute Myeloid L... | ATAC Therapy | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Efficacy Study for AC220 to Treat Acute Myeloid Leukemia (AML) | NCT00989261 | Acute Myeloid L... | Compound AC220 | 18 Years - 85 Years | Daiichi Sankyo | |
| Maintenance Azacitidine in Elderly Patients With Acute Myeloid Leukemia (AML) in CR After Induction Chemotherapy | NCT00387647 | Leukemia | Azacitidine | 60 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | NCT02523976 | Acute,Leukemia,... | Dasatinib prednisone cyclophosphamid... daunorubicin vincristine cytarabine mercaptopurine methotrexate dexamethasone mitoxantrone etoposide allogeneic hema... autologous hema... | 18 Years - 55 Years | Institute of Hematology & Blood Diseases Hospital, China | |
| A Trial to Establish the Feasibility of Combining Either the Tyrosine Kinase Inhibitor AC220,CXCR4 Inhibitor Plerixafor or HSP90 Inhibitor Ganetespib With Chemotherapy in Older Patients With Acute Myeloid Leukaemia and High Risk Myelodysplastic Syndrome. | NCT01236144 | Acute Myeloid L... High Risk Myelo... | Plerixafor AC220 Ganetespib | 60 Years - | Cardiff University | |
| EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL) | NCT01186328 | Lymphoblastic L... Lymphoblastic L... Leukemia, Lymph... Leukemia, Lymph... | EZN-3042 Cytarabine Doxorubicin Prednisone Vincristine PEG-asparaginas... Methotrexate Hydrocortisone | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations | NCT02381886 | Advanced Malign... | IDH305 | 18 Years - | Novartis | |
| AC220 for Children With Relapsed/Refractory ALL or AML | NCT01411267 | Lymphoblastic L... Myelogenous Leu... | AC220 Cytarabine Etoposide Methotrexate | 1 Month - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML | NCT01861002 | Lymphoblastic L... Myelogenous Leu... | Azacytidine Fludarabine Cytarabine Intrathecal (IT... Intrathecal Met... | 1 Year - 21 Years | Therapeutic Advances in Childhood Leukemia Consortium | |
| Mismatched Donor Cells to Treat Acute Myeloid Leukemia | NCT01793025 | Acute Myeloid L... | ATAC Therapy | 18 Years - | Maisonneuve-Rosemont Hospital | |
| Safety, Pharmacokinetics and Pharmacodynamics of TKI258 in Subjects With Acute Myeloid Leukemia | NCT00279773 | Acute Myeloid L... | TKI258 | 18 Years - | Novartis |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
